论文部分内容阅读
目的:探讨吸入糖皮质激素与β2受体激动剂治疗稳定期COPD的临床疗效。方法:选取2012年1月到2014年1月我院收治的稳定期COPD患者74例,随机分为观察组和对照组各37例,对照组患者入院后给予常规治疗;观察组患者在对照组治疗基础上,加用糖皮质激素和β2受体激动剂吸入治疗,比较两组患者的治疗有效率和肺功能水平。结果:经上述治疗后,观察组患者的治疗有效率为91.9%,明显高于对照组的78.4%;且观察组患者的FEV1及FEV1/FVC值均显著优于对照组,上述三项指标的组间差异均有统计学意义(P<0.05)。结论:吸入糖皮质激素与β2受体激动剂能够明显提高稳定期COPD患者的治疗有效性,促进患者肺部功能的恢复,提高预后质量,可推广使用。
Objective: To investigate the clinical efficacy of inhaled corticosteroids and β2 receptor agonists in the treatment of stable COPD. Methods: A total of 74 patients with stable COPD admitted to our hospital from January 2012 to January 2014 were randomly divided into observation group (37 cases) and control group (37 cases). Patients in the control group were given conventional therapy after admission. In the control group On the basis of treatment, plus glucocorticoid and β2 receptor agonist inhalation therapy, the treatment efficiency and lung function of the two groups were compared. Results: After the above treatment, the effective rate of the observation group was 91.9%, which was significantly higher than that of the control group (78.4%). The FEV1 and FEV1 / FVC values of the observation group were significantly better than those of the control group Differences between groups were statistically significant (P <0.05). Conclusion: Inhaled glucocorticoid and β2 agonist can significantly improve the therapeutic efficacy of stable COPD patients, promote the recovery of lung function and improve the quality of prognosis, which can be used widely.